How does DexCom, Inc. turn continuous glucose sensing into a scalable, subscription-like business?
DexCom, Inc. sells continuous glucose monitors and recurring sensors, pairing devices with data services to drive repeat revenue and stickiness. This matters because in 2025 DexCom reported strong sensor revenue growth and rising adoption beyond Type 1, signaling platform scalability.
Monitor sales feed a sensor-replacement cadence and data integrations, boosting lifetime value; analysts should watch sensor average selling price and subscription uptake. See product context: DexCom BCG Matrix Analysis
What Does DexCom Actually Sell?
DexCom, Inc. sells a wearable continuous glucose monitoring (CGM) ecosystem: disposable body sensors and transmitters that stream glucose readings to phones/receivers, plus subscription-enabled analytics via CLARITY; customers pay for sensors, transmitters, and recurring software/servicing that deliver real-time glucose intelligence and alerts.
Core hardware and software suite
DexCom's primary products are the G7 and legacy G6 systems: a small disposable sensor plus a transmitter that sends readings every five minutes, and the CLARITY analytics platform that turns raw data into Time – in – Range metrics and trend insights; in late 2024 DexCom added Stelo, an OTC CGM for Type 2 patients not on insulin.
Customer segments
Primary buyers are people with diabetes (Type 1 and insulin – using Type 2), newly targeted non – insulin Type 2 consumers via Stelo, and healthcare providers and payers who adopt CGM for clinical care and remote monitoring; hospitals and device integrators buy at scale for programs.
Value delivered to customers
Customers get near real – time glucose visibility (readings every five minutes), predictive alerts to prevent hypo/hyperglycemia, Time – in – Range tracking for treatment optimization, and cloud reports for clinicians – CLARITY translates data into actionable care improvements.
Differentiators and ease of purchase
DexCom stands out for sensor accuracy, frequent data transmission, smartphone integrations and partnerships with insulin pump makers; revenue mixes hardware sales, recurring sensor subscriptions and software/clinic integrations – see Competitive Landscape of DexCom Company for context.
DexCom SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Does DexCom Run Its Business Day to Day?
DexCom, Inc. runs daily with high-volume automated manufacturing and a pharmacy-first distribution model that ships disposable sensors and transmitters to patients and partners; commercial ops, supply chain, and technical integrations with pump makers keep sensor data flowing into automated insulin delivery systems.
Operating model: automated manufacturing meets pharmacy distribution
Production, fulfillment, and clinical support are synchronized: automated lines in major plants produce sensors, ERP and MES systems track yields and defects, and a pharmacy-led distribution network manages prescriptions and reimbursement.
Product delivery: prescription to patient through retail pharmacies
Patients obtain sensors and transmitters via retail pharmacies (now ~80% of US volume), with e-prescriptions and pharmacy fulfillment reducing wait times vs DME channels and improving adherence.
Production and sourcing: scaled, low-defect manufacturing
Major facilities in Arizona and Malaysia run automated assembly and clean-room sensor fabrication, producing millions of disposable sensors annually with continuous quality monitoring to keep defect rates low and throughput high.
Sales channels: retail pharmacies, provider networks, and partners
Retail pharmacy is the dominant US channel; additional volume flows through provider prescriptions, hospital systems, and partner bundles with pump manufacturers, supporting both direct-to-patient and institutional sales.
Key assets and partnerships: devices, data platform, and pump integrations
Core assets include sensor/transmitter hardware, a cloud data platform, and integrations with insulin pump makers such as Insulet and Tandem; these partnerships embed DexCom continuous glucose monitoring into automated insulin delivery ecosystems.
What makes the model work: scale, distribution shift, and clinical integration
Efficiency comes from automated manufacturing scale, pharmacy-centric distribution that accelerates patient access, and tight technical partnerships that increase sensor stickiness inside CGM-driven care pathways – driving recurring sensor revenue and higher lifetime customer value.
For more on market implications and growth drivers see Growth Outlook of DexCom Company.
DexCom Business Model Canvas
- One-time Payment
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
How Does Revenue Flow Through DexCom?
Revenue flows through DexCom, Inc. primarily via recurring sensor sales, supported by insurance reimbursements, cash purchases, and growing international sales; demand from installed users converts into predictable subscription-like repeat purchases for sensors and transmitters.
Main revenue: recurring disposable sensors
About 90 percent of Dexcom business model revenue comes from recurring disposable sensors sold to active users; sensors are consumed regularly, creating a razor-and-blade dynamic where device adoption converts into continuous sensor sales.
Additional streams: transmitters, receivers, international sales
Transmitters and receivers provide upfront device revenue and occasional replacements; international sales now make up nearly 30 percent of total revenue, and over-the-counter cash purchases add direct-to-consumer income.
Pricing and monetization: razor-and-blade with payer reimbursement
Dexcom monetizes via recurring unit sales priced to payers and consumers, combining insurance reimbursements (private and Medicare) with direct cash for OTC items; gross margins are maintained through scale in manufacturing, with margins typically between 61 and 63 percent.
What drives revenue most: installed base and reimbursement
Growth depends on expanding the global installed base (now > 2.5 million users) and payer coverage; for fiscal 2025, Dexcom is projected to generate over $4.6 billion in revenue, growing ~15 – 20 percent annually as sensor consumption per user and international penetration rise.
See related company context in this piece on the firm: History and Background of DexCom Company
DexCom Marketing Mix
- Complete Marketing Mix Analysis
- Effortlessly Communicate Your Business Strategy
- Investor-Ready Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Makes DexCom's Model Sustainable or Fragile?
DexCom, Inc.'s model is sustainable through high switching costs and large untapped Type 2 market but fragile versus aggressive pricing from Abbott and potential long-term shifts from GLP-1-driven metabolic change. Structural strengths include data lock-in and integrations; main risks are pricing pressure, changing insulin dependency, and reimbursement dynamics.
High switching costs and ecosystem lock-in
Patients and clinicians integrate Dexcom continuous glucose monitoring into pump loops, EHRs, and care workflows, creating friction to switch. This stickiness supports recurring sensor and transmitter revenue and underpins recurring subscription cash flow.
Large untapped Type 2 opportunity
Non-insulin-using Type 2 diabetics represent a multi-year runway; expanding indications and consumer adoption push Dexcom revenue streams beyond insulin-dependent users. Management targets broader metabolic health use cases to scale ARPU and unit sales.
Dependencies on pricing, reimbursement, and device accuracy
Revenue relies on favorable insurance coverage, Medicare/Medicaid policy, and sustained premium pricing versus Abbott's FreeStyle Libre. Supply-chain and manufacturing scale also constrain growth if demand surges.
Durability assessment for 2025 – 2026
For 2025 and into 2026, DexCom, Inc. appears resilient: superior sensor accuracy and integrations keep it a high-growth leader and justify premium pricing, while GLP-1 adoption and Abbott competition pose material medium-term downside risks to TAM and margins.
Key metrics reinforcing the view: in fiscal 2025 Dexcom reported reported revenue of $4.6 billion, year-over-year device and sensor growth supporting gross margin expansion to roughly 63%, and R&D spend near $650 million to sustain product features and regulatory approvals; sensor average selling price and subscription mix remain central to margin sensitivity. See market positioning in Target Customers and Market of DexCom Company
DexCom Boston Consulting Group Matrix
- Built by Experts, Trusted by Consultants
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What Is the History of DexCom Company and How Did It Evolve?
- What Is the Competitive Landscape of DexCom Company and How Does It Compete?
- What Is the Growth Outlook of DexCom Company and Where Is It Heading?
- How Does DexCom Company Reach Customers and Turn Demand into Sales?
- What Do the Mission, Vision, and Core Values of DexCom Company Reveal?
- Who Are the Core Customers in DexCom Company's Target Market?
- Who Owns DexCom Company Today and Who Holds Control?
Frequently Asked Questions
DexCom sells a continuous glucose monitoring ecosystem built around wearable sensors, transmitters, and software. Its G7 and G6 systems stream glucose readings to phones or receivers, while CLARITY turns that data into trend insights and Time-in-Range metrics. Stelo also expands the lineup for non-insulin Type 2 users.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.